The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
The new functionality complements Parse’s existing Evercode immune products
The research shows 93% of global companies now cover weight-management drugs in their health insurance plans
Subscribe To Our Newsletter & Stay Updated
